Cambridge Healthtech Institute’s 9th Annual

Engineering Antibody-Drug Conjugates
( 抗体药物复合体工程 )

Innovations for Next-Generation ADCs

2019年4月10~11日

 

By combining the selectivity of targeted treatment with the cytotoxic potency of chemotherapy drugs, ADCs hold the promise to revolutionize disease treatment, especially for cancer. However, the path toward ADC success is not without challenges. Using lessons learned from the past decade of ADC development, scientists are developing strategies for the third-generation antibody-drug conjugates by selecting the right target antigens, designing new payloads, optimizing linkers and engineering conjugation chemistries.

In this first installment of our 2-part ADC program, PEGS Boston’s 9th Annual Engineering Antibody-Drug Conjugates invites scientists to present their design strategies in increasing therapeutic index through novel payloads, alternative platforms and new linker conjugation technologies. 

Preliminary Agenda

KEYNOTE PRESENTATION: Targeting Immunotherapeutic Antibodies and Cytokines to Tumors Through Matrix Affinity Conjugates and Fusions

Jeffrey A. Hubbell, PhD, Eugene Bell Prof in Tissue Engineering, Institute of Molecular Engineering, University of Chicago

NEW PLATFORMS AND ALTERNATIVE FORMATS

Bispecific ADCs for Improved Tumor Targeting Specificity

David Liu, PhD, Director, Protein Engineering, Abbvie

Drug Conjugates Based on Engineered Affibody Molecules

Torbjörn Gräslund, PhD, Prof, Protein Science, KTH Royal Institute of Technology

NEW TARGETS AND NOVEL PAYLOADS

Towards a Deeper Understanding of the Immune Modulatory Properties of Cytotoxic Antibody-Drug Conjugates

Carl Uli Bialucha, Ph.D., Director, Oncology Biotherapeutics, Novartis Institutes for Biomedical Research, Inc.

Enabling Silvestrol as a Novel Payload for Antibody-Drug Conjugates

Thomas Pillow, PhD, Sr Scientist & Team Leader, Genentech

NAMPT Inhibitors as a Novel Payload Class for Antibody-Drug Conjugates

Chris Neumann, PhD, Principal Scientist, Medicinal Chemistry, Seattle Genetics

ADCs with Novel Kinesin Spindle Protein Inhibitor Payloads and A Tailor-Made Linker Chemistry

Hans-Georg Lerchen, PhD, Principal Scientist, Drug Discovery, Medicinal Chemistry, Bayer Pharmaceuticals

LINKER OPTIMIZATION AND CONJUGATION TECHNOLOGIES

Disulfide Re-Bridging with Pyrrolobenzodiazepine Dimers Enable the Formation of Homogeneous, Potent and Differentiated Full-Length Antibody and Fab-Fragments Drug Conjugates

Nazzareno Dimasi PhD, Associate Director R&D, MedImmune

Taming Randomness: A General Approach for Equimolar Conjugation of Proteins and Payloads

Sergii Kolodych, PhD, CSO, Syndivia

Turning Native Antibodies into Homogeneous ADCs without Antibody Engineering

Philipp Spycher, PhD, PSI Founder Fellow, Center for Radiopharmaceutical Sciences (CRS), Paul Scherrer Institute

Site-Selective, Serum Stable ADCs Using Next-Generation Maleimide Linkers

James Baker, PhD, Assoc Prof, Chemistry, University College London


* 活动内容有可能不事先告知作更动及调整。

Choose your language
Chinese
Japanese
Korean
English




Premier Sponsors


显示切换



免费电子邮件通知服务